eMedicine Specialties > Endocrinology > Metabolic Disorders

Lecithin-Cholesterol Acyltransferase Deficiency: Follow-up

Author: Vasudevan A Raghavan, MBBS, MD, MRCP, Assistant Professor, Division of Diabetes, Endocrinology, and Metabolism, Department of Internal Medicine, Ohio State University
Coauthor(s): Weerapan Khovidhunkit, MD, PhD, Clinical Instructor, Department of Medicine, Division of Endocrinology and Metabolism, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thailand
Contributor Information and Disclosures

Updated: Sep 18, 2007

Follow-up

Further Outpatient Care

  • Familial LCAT deficiency
    • Monitor renal function. This includes monitoring blood pressure, plasma BUN and creatinine values, 24-hour urine protein levels, and creatinine clearance.
    • Monitor visual acuity.
  • Fish eye disease: Corneal opacities may impair visual function.

Complications

  • Renal failure
  • Reduced vision from corneal opacities
  • Premature atherosclerosis
  • Anemia

Prognosis

  • Renal transplantation has been reported to be successful in some patients with familial LCAT deficiency, but it does not reverse the serum lipoprotein abnormalities or correct the anemia.
  • The risk of premature atherosclerosis associated with both familial LCAT deficiency and fish eye disease is only modestly increased.

Patient Education

For excellent patient education resources, visit eMedicine's Cholesterol Center and Statins Center. Also, see eMedicine's patient education articles High Cholesterol, Cholesterol FAQs, and Atorvastatin (Lipitor).

Miscellaneous

Medicolegal Pitfalls

  • The clinical and biochemical features of LCAT deficiency and fish eye disease are highly variable.
  • Measurements of plasma LCAT activity and the plasma cholesterol esterification rate and genetic testing for LCAT gene mutations are not routinely performed in most laboratories.
  • Referrals to experts in lipoprotein research are often required to make a definitive diagnosis.
 


More on Lecithin-Cholesterol Acyltransferase Deficiency

Overview: Lecithin-Cholesterol Acyltransferase Deficiency
Differential Diagnoses & Workup: Lecithin-Cholesterol Acyltransferase Deficiency
Treatment & Medication: Lecithin-Cholesterol Acyltransferase Deficiency
Follow-up: Lecithin-Cholesterol Acyltransferase Deficiency
References
[ CLOSE WINDOW ]

References

  1. Bérard AM, Clerc M, Brewer B, Santamarina-Fojo S. A normal rate of cellular cholesterol removal can be mediated by plasma from a patient with familial lecithin-cholesterol acyltransferase (LCAT) deficiency. Clin Chim Acta. Dec 2001;314(1-2):131-9. [Medline].

  2. Elkhalil L, Majd Z, Bakir R, et al. Fish-eye disease: structural and in vivo metabolic abnormalities of high-density lipoproteins. Metabolism. May 1997;46(5):474-83. [Medline].

  3. Hirano K, Kachi S, Ushida C, Naito M. Corneal and macular manifestations in a case of deficient lecithin: cholesterol acyltransferase. Jpn J Ophthalmol. Jan-Feb 2004;48(1):82-4. [Medline].

  4. Kuivenhoven JA, Pritchard H, Hill J, et al. The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. J Lipid Res. Feb 1997;38(2):191-205. [Medline].

  5. Mertens A, Verhamme P, Bielicki JK, et al. Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis. Circulation. Apr 1 2003;107(12):1640-6. [Medline].

  6. Pritchard PH, Hill JS. Genetic disorders of lecithin:cholesterol acyltransferase. In: Betterridge J, Illingworth R, Sheperd J, eds. Lipoproteins in Health and Disease. 799-814. ed. London, England: Hodder and Stoughton; 1999:799-814.

  7. Santamarina-Fojo S, Hoef J, Assmann G. Lecithin: cholesterol acyltransferase deficiency and fish-eye disease. In: Wonsiewicz M, Noujaim S, Boyle P, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York, NY: McGraw-Hill; 2001:2817-33.

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

LCAT deficiency, familial lecithin-cholesterol acyltransferase deficiency, familial LCAT deficiency, cholesterol acyltransferase deficiency, fish-eye disease, fish eye disease, high-density lipoprotein, HDL, low-density lipoprotein, LDL, atherosclerosis, renal failure, kidney failure, corneal opacities, visual impairment, hypoalphalipoproteinemia, opaque cornea, corneal opacity, progressive corneal opacification

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Vasudevan A Raghavan, MBBS, MD, MRCP, Assistant Professor, Division of Diabetes, Endocrinology, and Metabolism, Department of Internal Medicine, Ohio State University
Vasudevan A Raghavan, MBBS, MD, MRCP is a member of the following medical societies: American Association of Clinical Endocrinologists, American College of Physicians-American Society of Internal Medicine, American Diabetes Association, Endocrine Society, National Lipid Association, and Royal College of Physicians
Disclosure: Nothing to disclose.

Coauthor(s)

Weerapan Khovidhunkit, MD, PhD, Clinical Instructor, Department of Medicine, Division of Endocrinology and Metabolism, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thailand
Weerapan Khovidhunkit, MD, PhD is a member of the following medical societies: American Association of Clinical Endocrinologists, American College of Physicians, and Endocrine Society
Disclosure: Nothing to disclose.

Medical Editor

David M Klachko, MBBCh, Professor Emeritus, Department of Internal Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Missouri
David M Klachko, MBBCh is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians-American Society of Internal Medicine, American Diabetes Association, American Federation for Medical Research, Endocrine Society, Missouri State Medical Association, and Sigma Xi
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Kent Wehmeier, MD, Professor, Department of Internal Medicine, Division of Endocrinology, Diabetes, and Metabolism, St Louis University School of Medicine
Kent Wehmeier, MD is a member of the following medical societies: American Society of Hypertension, Endocrine Society, and International Society for Clinical Densitometry
Disclosure: Nothing to disclose.

CME Editor

Mark Cooper, MD, Head, Vascular Division, Baker Medical Research Institute; Professor of Medicine, Monash University
Disclosure: Nothing to disclose.

Chief Editor

George T Griffing, MD, Professor of Medicine, Director of General Internal Medicine, St Louis University
George T Griffing, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Medical Practice Executives, American College of Physician Executives, American College of Physicians, American Diabetes Association, American Federation for Medical Research, American Heart Association, Central Society for Clinical Research, and Endocrine Society
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.